Andrew J Massey

Summary

Affiliation: Granta Park
Country: UK

Publications

  1. doi A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells
    Andrew J Massey
    Vernalis R and D Ltd, Granta Park, Cambridge, CB21 6GB, UK
    Cancer Chemother Pharmacol 66:535-45. 2010
  2. pmc Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor
    Andrew J Massey
    Vernalis R and D Ltd, Granta Park, Cambridge, United Kingdom
    PLoS ONE 5:e13123. 2010
  3. pmc Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
    Christopher Bryant
    Vernalis R and D Ltd, Granta Park, Cambridge CB21 6GB, UK
    BMC Cancer 14:570. 2014
  4. pmc γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
    Rebecca Rawlinson
    Vernalis R and D Ltd, Granta Park, Cambridge, UK CB21 6GB
    BMC Cancer 14:483. 2014
  5. pmc Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells
    Christopher Bryant
    Vernalis R and D Ltd, Granta Park, Cambridge CB21 6GB, UK
    Mol Cancer 13:147. 2014
  6. pmc NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
    Michael Rugaard Jensen
    Novartis Institutes for BioMedical Research, Oncology Research, Klybeckstrasse 141, CH 4057 Basel, Switzerland
    Breast Cancer Res 10:R33. 2008
  7. doi Adenosine-derived inhibitors of 78 kDa glucose regulated protein (Grp78) ATPase: insights into isoform selectivity
    Alba T Macias
    Vernalis R and D Ltd, Granta Park, Great Abington, Cambridge, CB21 6GB, UK
    J Med Chem 54:4034-41. 2011
  8. doi Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design
    Douglas S Williamson
    Vernalis R and D Ltd, Granta Park, Great Abington, Cambridge CB21 6GB, United Kingdom
    J Med Chem 52:1510-3. 2009
  9. doi Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling
    Hana Tabusa
    Department of Oncology, Vernalis R and D Ltd, Granta Park, Cambridge, CB21 6GB, United Kingdom
    Mol Cancer Res 11:109-21. 2013

Collaborators

  • Douglas S Williamson
  • Martin J Drysdale
  • James B Murray
  • Nicolas Foloppe
  • Christopher Bryant
  • Rebecca Rawlinson
  • Hana Tabusa
  • Alba T Macias
  • Michael Rugaard Jensen
  • Kirsten Scriven
  • Teresa Brooks
  • Jenifer Borgognoni
  • Rachel Parsons
  • Lindsey Terry
  • Allan E Surgenor
  • Yikang Wang
  • Terry Shaw
  • Mike Wood
  • Christopher J Graham
  • Natalia Matassova
  • Pawel Dokurno
  • Zoe Daniels
  • Alexandra Clay
  • Rob Howes
  • Geraint L Francis
  • Nicola Allen
  • Patrick Chene
  • Cornelia Quadt
  • Thomas Radimerski
  • Josef Brueggen
  • Alan Buckler
  • Joseph Schoepfer
  • Carlos Garcia-Echeverria
  • Robert Cozens
  • Chantale T Guy

Detail Information

Publications9

  1. doi A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells
    Andrew J Massey
    Vernalis R and D Ltd, Granta Park, Cambridge, CB21 6GB, UK
    Cancer Chemother Pharmacol 66:535-45. 2010
    ....
  2. pmc Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor
    Andrew J Massey
    Vernalis R and D Ltd, Granta Park, Cambridge, United Kingdom
    PLoS ONE 5:e13123. 2010
    ..We have identified a novel inhibitor of these kinases and utilized this molecule to probe the functional interplay between these two checkpoints...
  3. pmc Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
    Christopher Bryant
    Vernalis R and D Ltd, Granta Park, Cambridge CB21 6GB, UK
    BMC Cancer 14:570. 2014
    ..Chk1 inhibitors may exhibit single agent anti-tumor activity in cancers with underlying DNA repair, DNA damage response or DNA replication defects...
  4. pmc γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
    Rebecca Rawlinson
    Vernalis R and D Ltd, Granta Park, Cambridge, UK CB21 6GB
    BMC Cancer 14:483. 2014
    ..Utilizing pharmacodynamic biomarkers to optimize drug dose and scheduling in these trials could greatly enhance the likelihood of clinical success...
  5. pmc Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells
    Christopher Bryant
    Vernalis R and D Ltd, Granta Park, Cambridge CB21 6GB, UK
    Mol Cancer 13:147. 2014
    ..Recent evidence suggests that Chk1 inhibitors may demonstrate significant single agent activity in tumors with specific DNA repair defects, a constitutively activated DNA damage response or oncogene induced replicative stress...
  6. pmc NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
    Michael Rugaard Jensen
    Novartis Institutes for BioMedical Research, Oncology Research, Klybeckstrasse 141, CH 4057 Basel, Switzerland
    Breast Cancer Res 10:R33. 2008
    ..HSP90 has emerged in recent years as a promising new target for anticancer therapies...
  7. doi Adenosine-derived inhibitors of 78 kDa glucose regulated protein (Grp78) ATPase: insights into isoform selectivity
    Alba T Macias
    Vernalis R and D Ltd, Granta Park, Great Abington, Cambridge, CB21 6GB, UK
    J Med Chem 54:4034-41. 2011
    ..X-ray crystal structures of Grp78 bound to ATP, ADPnP, and adenosine derivative 10 revealed differences in the binding site between Grp78 and homologous proteins...
  8. doi Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design
    Douglas S Williamson
    Vernalis R and D Ltd, Granta Park, Great Abington, Cambridge CB21 6GB, United Kingdom
    J Med Chem 52:1510-3. 2009
    ..Exposure of compound 12 to HCT116 cells caused significant reduction in cellular levels of Raf-1 and Her2 at concentrations similar to that which caused cell growth arrest...
  9. doi Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling
    Hana Tabusa
    Department of Oncology, Vernalis R and D Ltd, Granta Park, Cambridge, CB21 6GB, United Kingdom
    Mol Cancer Res 11:109-21. 2013
    ..These results support a role for the PAKs in the proliferation of mutant KRAS-driven colorectal carcinoma cells via pathways not involving RAF/MEK/ERK and PI3K/AKT signaling...